Table 1 Baseline characteristics of the AML study cohort (IDH^wildtype vs. IDH1^mutated or IDH2^mutated vs. pooled IDH1^mutated and IDH2^mutated).

Age (years)

363/363

298/298

26/26

39/39

0.389

65/65

0.242

Median

60.0

60.0

62.0

62.0

62.0

Range

18–90.0

18.0–90.0

31.0–82.0

27.0–81.0

27.0 – 82.0

Age ≤60 years (%)

50.1

182/363

50.7

151/298

46.2

12/26

48.7

19/39

0.891

47.7

31/65

0.663

Age >60 years (%)

49.9

181/363

49.3

147/298

53.8

14/26

51.3

20/39

52.3

34/65

Male sex (%)

57.6

209/363

56.7

169/298

69.2

18/26

56.4

22/39

0.459

61.5

40/65

0.476

AML history (%)

363/363

298/298

26/26

39/39

0.592

65/65

0.501

De novo AML

68.9

250/363

68.8

205/298

76.9

20/26

64.1

25/39

69.2

45/65

Secondary AML

25.1

91/363

24.5

73/298

23.1

6/26

30.8

12/39

27.7

18/65

Therapy-related AML

6.1

22/363

6.7

20/298

0.0

0/26

5.1

2/39

3.1

2/65

WBC at diagnosis (/µl)

356/363

292/298

26/26

38/39

0.733

64/65

0.464

Median

8.6

8.6

6.9

11.6

8.8

Range

0.3–284.0

0.3–284.0

0.7–206.1

0.9–146.3

0.7–206.1

Platelet count at diagnosis (/µl)

293/363

241/298

22/26

30/39

0.064

52/65

0.019

Median

55.0

50.0

83.5

94

85.5

Range

2.0–979.0

2.0–523.0

10.0–469.0

7.0–979.0

7.0–979.0

Hemoglobin (g/dl)

290/363

237/298

22/26

31/39

0.528

53/65

0.404

Median

9.2

9.1

9.6

9.3

9.6

Range

2.5–16.6

2.5–16.0

4.9–12.1

5.5–16.6

4.9–16.6

Blood blasts (%)

155/363

130/298

12/26

13/39

0.348

25/65

0.166

Median

38.3

33.0

55.5

46.7

46.7

Range

0.0–98.0

0.0–98.0

4.0–89.0

0.0–90.0

0.0–90.0

Bone marrow blasts (%)

131/363

108/298

17/26

15/39

0.421

23/65

0.256

Median

60.0

60.0

85.0

70.0

80.0

Range

0.0–100.0

0.0–99.0

20.0–96.0

8.0–100.0

8.0–100.0

Cytogenetic risk group (%)

342/363

279/298

25/26

38/39

0.436

63/65

0.403

Favorable

21.6

74/342

22.2

62/279

28.0

7/25

13.2

5/38

18.5

12/65

Intermediate

54.7

187/342

55.6

155/279

44.0

11/25

55.3

21/38

49.2

32/65

Adverse

23.7

81/342

22.2

62/279

28.0

7/25

31.6

12/38

29.2

19/65

NPM1 mutation (%)

16.8

61/363

17.4

52/298

18.2

4/22

14.7

5/34

0.807

13.8

9/65

0.570

FLT3-ITD presence (%)

15.4

56/363

15.8

47/298

22.7

5/22

11.8

4/34

0.551

13.8

9/65

0.792

ECOG performance status (%)

358/358

294/294

26/26

38/38

0.656

68/68

0.809

ECOG 0-1

65.4

234/358

65.6

193/294

57.7

15/26

68.4

26/38

64.1

41/64

ECOG 2-4

34.6

124/358

34.4

101/294

42.3

11/26

31.6

12/38

35.9

23/64

Antecedent CMML (%)

2.5

9/363

1.7

5/298

3.8

1/26

7.7

3/39

0.068

6.2

4/65

0.035

Intensive induction therapy (%)

82.2

295/359

82.3

242/294

84.6

22/26

79.5

31/39

0.860

81.5

53/65

0.883

Anthracyclines (mg/m²)

Median

240.0

295/359

240.0

242/294

240.0

22/26

192.0

31/39

0.242

192.0

53/65

0.186

Range

0.0–360.0

0.0–360.0

60.0–360.0

144.0–360.0

60.0–360.0

Consolidation type (%)

312/358

252/298

24/26

36/36

60/60

Chemotherapy

37.8

118/312

36.1

91/252

45.8

11/24

44.4

16/36

0.440

45.0

27/60

0.202

alloHCT

62.2

194/312

63.9

161/252

54.2

13/24

55.6

20/36

55.0

33/60